SCHEMBL20351362

SCHEMBL20351362

CC(C)(NS(=O)(=O)c1cccc(OCC(F)F)c1)c1ccc(CN2CC(=O)NC2O)cc1

nearest known ligand 0.64

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ DUT P33316 15/20 0.64
▸ HCRTR1 O43613 2/20 0.34
▸ HCRTR2 O43614 2/20 0.34
▸ ACACB O00763 2/20 0.34
▸ SPHK2 Q9NRA0 1/20 0.33
▸ SPHK1 Q9NYA1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20374165 0.85 DUT (0.67) DUT
SCHEMBL20351363 0.83 DUT (0.68) DUT
SCHEMBL24153844 0.80 DUT (0.41) DUTHCRTR1HCRTR2
SCHEMBL18379760 0.80 DUT (0.66) DUTACACB
SCHEMBL12630519 0.77 DUT (0.66) DUT
SCHEMBL12629741 0.77 DUT (0.76) DUT
SCHEMBL21690618 0.73 DUT (0.65) DUT
SCHEMBL21536598 0.72 DUT (0.70) DUT
SCHEMBL26022939 0.69 DUT (0.50) DUT
SCHEMBL20204782 0.69 DUT (0.68) DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10570098-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-02-25 — — US disclosed
US-10562860-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-02-18 — — US disclosed
US-20180194736-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-07-12 — — US disclosed
US-20180186737-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180194736-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885HCRTR1 4179/4885HCRTR2 4432/4885
US-10570098-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD DUT 1/4885HCRTR1 4179/4885HCRTR2 4432/4885
US-10562860-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD DUT 1/4885HCRTR1 4179/4885HCRTR2 4432/4885
US-20180186737-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885HCRTR1 4179/4885HCRTR2 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback